• Karunanithi M Centre for Advanced Research in Indian System of Medicine, Shanmugha Arts, Science, Technology and Research Academy Deemed University, Thanjavur, Tamil Nadu, India.
  • David Raj C Centre for Advanced Research in Indian System of Medicine, Shanmugha Arts, Science, Technology and Research Academy Deemed University, Thanjavur, Tamil Nadu, India.
  • Brindha P Centre for Advanced Research in Indian System of Medicine, Shanmugha Arts, Science, Technology and Research Academy Deemed University, Thanjavur, Tamil Nadu, India.
  • Jegadeesan M Department of Environmental Sciences and Medicinal Botany, Tamil University, Thanjavur, Tamil Nadu, India.
  • Kavimani S Department of Pharmacology, College of Pharmacy, Mother Theresa Post Graduate and Research Institute of Health Sciences, Puducherry, India.



Mucuna pruriens, Cochinchinesis, Utilis, Deeringiana, Antiparkinson activity


Objective: The aim was to study the antiparkinson activity in the seed extracts of four species of Mucuna.

Methods: The hydroalcoholic extracts of seeds of four species of Mucuna were evaluated for antiparkinson activity of after a preliminary phytochemical study. The activity was measured in rats by indirectly measuring the decrease in malondialdehyde level, decrease in tongue protrusion frequency, and reduction in vacuous chewing movement after administering reserpine at the dose of 1 mg/kg. The dose levels of four species of Mucuna seed extract were kept at 100, 200, and 300 mg/Kg.

Results: Extracts exhibited potent antiparkinson activity and achieved statistically significant p values compared with control group. The study corroborates and compares all four species of Mucuna.

Conclusion: Among the extracts, the highest percentage of antiparkinson activity was recorded for Mucuna pruriens.


Download data is not yet available.


Hussain G, Manyam BV. Mucuna pruriens proves more effective than L-DOPA in Parkinson’s disease animal model. Phytotherapy Res 1997;11:419-23.

Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem 2011;118:939-57.

Stoessl JA. Etiology of Parkinson’s disease. Can J Neuorol 1999;26:S5- 12.

Cheryl HW. Diagnosis and Management of Parkinson’s Disease. 6th ed. New York: Professional Communications Inc.; 2008. p. 4-25.

Sathiyanarayanan L, Arulmozhi S. Mucuna pruriens Linn.-A comprehensive review. Pharmacogn Rev 2007;1:157-62.

Ganthi AS, Vijayambika C, Jegadeesan M. Comparative L-dopa and anti-nutritional contents in seed materials of market samples of Mucuna pruriens (L) DC. Int J Res Ayurveda Pharm 2010;1:480-3.

Vijayambika C. Pharmacognostical Studies on Mucuna pruriens (L.) DC and its Adulterants. Thanjavur, India: Department of Siddha Medicine, Tamil University; 2003. Kay L. The Microscopical Study of Drugs. London, Bailliere: Tindall and Cox; 1938. p. 45.

Johnson DA. Plant Microtechnique. New York: McGraw Hill Book Company; 1940. p. 182-3.

Birch HF, Doughty LR. The distribution and interrelationships of the alkaloids in the bark of Cinchona ledgeriana. Biochem J 1948;43:38- 44.

Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.

Seigler DS, Seilheimer S, Keesy J, Huang HF. Tannins from four common Acacia Species of Texas and Northeastern Mexico. Econ Bot 1986;40:220-32.

Bray HG, Thorpe WV. Analysis of phenolic compounds of interest in metabolism. Methods Biochem Anal 1954;1:27-52.

Abbott B, Starr BS, Starr MS. CY 208-243 behaves as a typical D-1 agonist in the reserpine-treated mouse. Pharmacol Biochem Behav 1991;38:259-63.

Vogel WH, Bernward AS, Jürgen S, Günter M, Vogel WF. Drug Discovery and Evaluation Pharmacological Assays. 2nd ed. Berlin, Heidelberg, New York: Springer-Verlag; 2002. p. 577-85.

Neisewander JL, Castañeda E, Davis DA. Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: Support for a model of tardive dyskinesia. Psychopharmacology (Berl) 1994;116:79-84.

Neisewander JL, Castañeda E, Davis DA, Elson HJ, Sussman AN. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Eur J Pharmacol 1996;305:13-21.

Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazide, reserpine and electroconvulsive therapy. Psychopharmacology 1960;1:408-18.

Bergamo M, Abílio VC, Queiroz CM, Barbosa-Júnior HN, Abdanur LR, Frussa-Filho R, et al. Effects of age on a new animal model of tardive dyskinesia. Neurobiol Aging 1997;18:623-9.

Krause E, Gürkov R. Local botulinum neurotoxin A therapy in tardive lingual dyskinesia. Laryngorhinootologie 2009;88:508-10.

Florang VR, Rees JN, Brogden NK, Anderson DG, Hurley TD, Doorn JA, et al. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology 2007;28:76-82.

Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008;115:193-203.

Kulkarni SK, Naidu PS. Isoniazid induced orofacial dyskinesia in rats: An experimental model for tardive dyskinesia. Indian J Pharmacol 2001;33:286-8.

Dutra RC, Andreazza AP, Andreatini R, Tufik A, Vital MA. Behavioral effects of MK-801 on reserpine-treated mice. Progress in Neuro-24. Psychopharmacol Biol Psychiatry 2002;26:487-95.

Hornykiewiez O. Dopamine and brain function. Pharmacol Rev 1966;18:925-64.

Kasireddy P, Khumanthem D S, Prashanti P, Manguluri P. Neuoprotective potential and efficacy of neurodegenerative disorders of fruit extract of Aegle marmelos. Int J Pharm Pharm Sci 2015;7:155- 9.

Colpaert FC. Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 1987;26:1431-40.

Kaur S, Starr MS. Antiparkinsonian action of dextromethorphan in the reserpine-treated mouse. Eur J Pharmacol 1995;280:159-66.

Menzaghi F, Whelan KT, Risbrough VB, Rao TS, Lloyd GK. Interactions between a novel cholinergic ion channel agonist, SIB- 1765F and L-DOPA in the reserpine model of Parkinson’s disease in rats. J Pharmacol Exp Ther 1997;280:393-401.

Skalisz LL, Beijamini V, Joca SL, Vital MA, Da Cunha C, Andreatini R, et al. Evaluation of the face validity of reserpine administration as an animal model of depression-parkinson’s disease association. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:879-83.

Javid M, Archana P. Evaluation of anti-obesity effect of aqueous extract of Mucuna pruriens seeds on rats. Int J Pharm Pharm Sci 2017;9:111-5.

Fachinetto R, Burger ME, Wagner C, Wondracek DC, Brito VB, Nogueira CW, et al. High fat diet increases the incidence of orofacial dyskinesia and oxidative stress in specific brain regions of rats. Pharmacol Biochem Behav 2005;81:585-92.

Pivovarova NB, Nguyen HV, Winters CA, Brantner CA, Smith CL, Andrews SB. Excitotoxic calcium overload in a subpopulation of mitochondria triggers delayed death in hippocampal neurons. J Neurosci 2004;16:5611-2.

Hernández-Fonseca K, Cárdenas-Rodríguez N, Pedraza-Chaverri J, Massieu L. Calcium-dependent production of reactive oxygen species is involved in neuronal damage induced during glycolysis inhibition in cultured hippocampal neurons. J Neurosci Res 2008;86:1768-80.

Windelborn JA, Lipton P. Lysosomal release of cathepsins causes ischemic damage in the rat hippocampal slice and depends on NMDA-mediated calcium influx, arachidonic acid metabolism, and free radical production. J Neurochem 2008;106:56-9.

Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, Sehara Y, et al. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats. Brain Res 2007;1176:143-50.

Sussman AN, Tran-Nguyen LT, Neisewander JL. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. Eur J Pharmacol 1997;337:157-60.



How to Cite

M, K., D. Raj C, B. P, J. M, and K. S. “PHYTOCHEMICAL ANALYSIS AND COMPARATIVE ANTIPARKINSON ACTIVITY OF FOUR SPECIES OF MUCUNA”. Asian Journal of Pharmaceutical and Clinical Research, vol. 11, no. 7, July 2018, pp. 125-31, doi:10.22159/ajpcr.2018.v11i7.18959.



Original Article(s)

Most read articles by the same author(s)